GLPG vs. AMRX, EVO, GPCR, AGIO, RNA, NAMS, RCKT, SNDX, CPRX, and SDGR
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Amneal Pharmaceuticals (AMRX), Evotec (EVO), Structure Therapeutics (GPCR), Agios Pharmaceuticals (AGIO), Avidity Biosciences (RNA), NewAmsterdam Pharma (NAMS), Rocket Pharmaceuticals (RCKT), Syndax Pharmaceuticals (SNDX), Catalyst Pharmaceuticals (CPRX), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.
32.5% of Galapagos shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Galapagos has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.
Galapagos presently has a consensus target price of $34.50, indicating a potential upside of 18.60%. Amneal Pharmaceuticals has a consensus target price of $7.31, indicating a potential upside of 8.17%. Given Galapagos' higher probable upside, equities analysts plainly believe Galapagos is more favorable than Amneal Pharmaceuticals.
Galapagos received 459 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
In the previous week, Amneal Pharmaceuticals had 11 more articles in the media than Galapagos. MarketBeat recorded 21 mentions for Amneal Pharmaceuticals and 10 mentions for Galapagos. Amneal Pharmaceuticals' average media sentiment score of 0.33 beat Galapagos' score of 0.17 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.
Galapagos has higher earnings, but lower revenue than Amneal Pharmaceuticals. Galapagos is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amneal Pharmaceuticals has a net margin of -6.76% compared to Galapagos' net margin of -26.25%. Amneal Pharmaceuticals' return on equity of 234.06% beat Galapagos' return on equity.
Summary
Amneal Pharmaceuticals beats Galapagos on 13 of the 18 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
